As of 2025-03-17, the Relative Valuation of Syros Pharmaceuticals Inc (SYRS) is (37.92) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.09 USD, the upside of Syros Pharmaceuticals Inc based on Relative Valuation is -41134.2%.
The range of the Relative Valuation is (18.59) - (56.14) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 4.6x - 16.5x | 10.6x |
| Forward P/E multiples | 5.1x - 15.4x | 10.2x |
| Fair Price | (18.59) - (56.14) | (37.92) |
| Upside | -20222.5% - -60862.2% | -41134.2% |
| Date | P/E |
| 2025-03-05 | -0.02 |
| 2025-03-04 | -0.02 |
| 2025-03-03 | -0.02 |
| 2025-02-28 | -0.04 |
| 2025-02-27 | -0.04 |
| 2025-02-26 | -0.04 |
| 2025-02-25 | -0.04 |
| 2025-02-24 | -0.05 |
| 2025-02-21 | -0.05 |
| 2025-02-20 | -0.05 |
| 2025-02-19 | -0.05 |
| 2025-02-18 | -0.05 |
| 2025-02-14 | -0.05 |
| 2025-02-13 | -0.05 |
| 2025-02-12 | -0.05 |
| 2025-02-11 | -0.05 |
| 2025-02-10 | -0.05 |
| 2025-02-07 | -0.05 |
| 2025-02-06 | -0.05 |
| 2025-02-05 | -0.05 |
| 2025-02-04 | -0.05 |
| 2025-02-03 | -0.05 |
| 2025-01-31 | -0.05 |
| 2025-01-30 | -0.05 |
| 2025-01-29 | -0.05 |
| 2025-01-28 | -0.05 |
| 2025-01-27 | -0.06 |
| 2025-01-24 | -0.06 |
| 2025-01-23 | -0.06 |
| 2025-01-22 | -0.06 |
| 2025-01-21 | -0.06 |
| 2025-01-17 | -0.06 |
| 2025-01-16 | -0.06 |
| 2025-01-15 | -0.07 |
| 2025-01-14 | -0.07 |
| 2025-01-13 | -0.06 |
| 2025-01-10 | -0.06 |
| 2025-01-08 | -0.06 |
| 2025-01-07 | -0.06 |
| 2025-01-06 | -0.07 |
| 2025-01-03 | -0.07 |
| 2025-01-02 | -0.06 |
| 2024-12-31 | -0.06 |
| 2024-12-30 | -0.07 |
| 2024-12-27 | -0.06 |
| 2024-12-26 | -0.06 |
| 2024-12-24 | -0.06 |
| 2024-12-23 | -0.06 |
| 2024-12-20 | -0.05 |
| 2024-12-19 | -0.06 |